Medibank’s cyber breach is much worse than expected
Nick Sundich, October 25, 2022
Medibank (ASX:MPL) customers and investors have learned that the cybercrime against the company was worse than had been feared. The company gave an update to the ASX this morning on the news, but it remains to be seen how investors will respond.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Medibank data breach gets worse
Medibank, its investors and customers already knew that a criminal stole the login credentials of someone with high-level systems access and sold the data. The company had been piecing together just how its system was penetrable.
Although this was first detected two weeks ago, Medibank had believed it was confined to its budget subsidiary ahm and data collected about international students who used Medibank under its OSHC service.
This morning, the company confirmed data from its main brand was also compromised and that criminals stepped up extortion demands by providing another 1000 customers’ details.
The company set to be punished
At the very least, we think shareholders will punish the company’s share price when trading resumes. Medibank shares are in a trading halt until tomorrow. But it also remains to be seen if it will cop any penalties over the incident.
Medibank (ASX:MPL) share price chart (Graph: TradingView)
The company announced a customer support package including 24/7 mental health and wellbeing support and had deferred premium increases until January next year.
Investors who do not hold shares in Medibank may not be concerned about this incident. But we think they should take notice that the risk of cybercrime against companies is realistic, can occur unexpectedly and cause significant damage to a company’s reputation and potentially its finances.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Can Gold Hit $4,000 in 2025? These 5 ASX Stocks Could Soar if It Does
In our view, the question isn’t just whether gold can hit $4,000 an ounce in 2025; it’s about what happens…
Qantas Board Shake-Up: Is Investor Pressure Finally Taking Effect?
Qantas Airways, Australia’s flagship airline, has long been a symbol of national pride, maintaining a central position in the country’s…
Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product
Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…